Beyond PD-1/PD-L1: TME-Targeted Therapies in the Era of Immunotherapy Resistance. J Biomol Pathog Ther. 2026;2(1). Accessed April 8, 2026. https://jbptjournal.org/index.php/jbpt/article/view/33